Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$883.70 USD

883.70
351,300

-6.98 (-0.78%)

Updated Apr 26, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US

by Zacks Equity Research

The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

by Zacks Equity Research

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day.

Ethan Feller headshot

Bull of the Day: Regeneron Pharmaceuticals (REGN)

by Ethan Feller

The Biotechnology company enjoys a litany of bullish catalysts on the horizon

Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

by Zacks Equity Research

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

by Zacks Equity Research

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use

by Zacks Equity Research

FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

by Zacks Equity Research

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know

by Zacks Equity Research

Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results

by Zacks Equity Research

Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

by Zacks Equity Research

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint

by Zacks Equity Research

Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

by Zacks Equity Research

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Sweta Killa headshot

5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016

by Sweta Killa

The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.

Ekta Bagri headshot

3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024

by Ekta Bagri

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Select Medical (SEM) Unveils Separation Plan for Concentra

by Zacks Equity Research

Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.

Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?

by Zacks Equity Research

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Best Momentum Stocks to Buy for January 3rd

by Zacks Equity Research

SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.

Nalak Das headshot

Top 5 Momentum Picks for January After a Fabulous 2023

by Nalak Das

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.